Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
Completed · Early Phase 1
Conditions studied: Metastatic Breast Cancer
In brief
To assess longitudinal changes in allele frequency of ESR1 mutation in plasma in patients treated with Fulvestrant plus palbociclib compared to tamoxifen plus palbociclib
Key facts
- Study ID
- NCT02913430
- Run by
- Shannon Puhalla
- People needed
- 7
- Starts
- 2018-04-24
- Expected to finish
- 2024-04-30
- Last updated by the study team
- 2024-09-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Magee-Womens Hospital UPMC — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.